NextPlat Sees $55M 2025 Revenue as Q4 340B Sales Jump 90%+
NextPlat expects approximately $55 million in 2025 revenue with fourth-quarter 340B healthcare revenue up over 90% sequentially and prescription volume rising 7%. The company targets 20–25% gross margin in first-quarter 2026, while cutting operating costs and sustaining $13 million cash, $15 million working capital and zero unsecured debt.
1. Revenue Guidance and Healthcare Operations Performance
NextPlat expects about $55 million revenue in 2025 and preliminary fourth-quarter results show 340B healthcare revenue up over 90% sequentially with prescription volume rising 7%, reflecting enhanced engagement initiatives and operational improvements in its healthcare operations.
2. Gross Margin Expansion Outlook
The company anticipates consolidated gross margin of 20–25% in first-quarter 2026, driven by its shift toward higher-margin contracted services, including expanded 340B and medication fulfillment contracts, with further incremental improvement projected throughout 2026.
3. Cost Reduction and Operational Efficiency
Structural overhead initiatives aimed at reducing annual operating expenses include closing underutilized office space, personnel consolidation, reduced reliance on external consultants and enhanced logistics efficiencies, supporting sustained cost discipline and process efficiency.
4. Liquidity Position and Forecasted Loss Reduction
NextPlat maintains solid liquidity with approximately $13 million in cash, $15 million working capital and zero unsecured debt as of December 31, 2025, and expects meaningful reductions in operating losses by the end of second-quarter 2026 based on early first-quarter momentum.